| Title |
Adaptive RadioTherapy for Locally Advanced OroPharynx Cancer (ART-OPC) A Phase II Randomized Trial |
| Protocole ID |
ART-OPC |
| ClinicalTrials.gov ID |
NCT04901234 |
| Cancer Type(s) |
Head and Neck |
| Phase |
Phase II |
| Stage |
|
| Study Type |
Clinical |
| Drug |
|
| Institution |
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
| City |
|
| Principal Investigator |
Dr. Houda Bahig
|
| Coordinator |
Silvine Benth
514-890-8000
|
| Status |
Recruiting |
| Activation Date |
|
| Eligibility Criteria |
- Age ≥18 years
- Ability to provide written informed consent.
- Stage T3-T4N0-3 as per AJCC 8th edition
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Biopsy proven diagnosis of squamous cell carcinoma of the oropharynx.
- Planned for curative radiotherapy +/- chemotherapy
- For females of child-bearing age, a negative pregnancy test
- Patients treated with induction chemotherapy can be included if they have residual tumor in place.
|
| Exclusion Criteria |
- Previous irradiation of the head and neck (HNC) region, excluding superficial radiation therapy for non-melanomatous skin cancer
- Previous surgery of the HNC region (except for incisional or excisional biopsies)
- Pregnancy or breastfeeding
- Connective tissue disease
- Any medical condition that could, in the opinion of the investigator, prevent follow-up after radiotherapy.
- Patients with contra-indications to MRI will be excluded.
|
| |
|
Groupe d'étude en oncologie du Québec